Cargando…

Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma

Melanoma is a deadly disease that often exhibits relentless progression and can have both early and late metastases. Recent advances in immunotherapy and targeted therapy have dramatically increased patient survival for patients with melanoma. Similar advances in molecular targeted PET imaging can i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vercellino, Laetitia, de Jong, Dorine, Dercle, Laurent, Hosten, Benoit, Braumuller, Brian, Das, Jeeban Paul, Deng, Aileen, Moya-Plana, Antoine, A’Keen, Camry, Yeh, Randy, Merlet, Pascal, Baroudjian, Barouyr, Salvatore, Mary M., Capaccione, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139963/
https://www.ncbi.nlm.nih.gov/pubmed/35626272
http://dx.doi.org/10.3390/diagnostics12051116
_version_ 1784714983432519680
author Vercellino, Laetitia
de Jong, Dorine
Dercle, Laurent
Hosten, Benoit
Braumuller, Brian
Das, Jeeban Paul
Deng, Aileen
Moya-Plana, Antoine
A’Keen, Camry
Yeh, Randy
Merlet, Pascal
Baroudjian, Barouyr
Salvatore, Mary M.
Capaccione, Kathleen M.
author_facet Vercellino, Laetitia
de Jong, Dorine
Dercle, Laurent
Hosten, Benoit
Braumuller, Brian
Das, Jeeban Paul
Deng, Aileen
Moya-Plana, Antoine
A’Keen, Camry
Yeh, Randy
Merlet, Pascal
Baroudjian, Barouyr
Salvatore, Mary M.
Capaccione, Kathleen M.
author_sort Vercellino, Laetitia
collection PubMed
description Melanoma is a deadly disease that often exhibits relentless progression and can have both early and late metastases. Recent advances in immunotherapy and targeted therapy have dramatically increased patient survival for patients with melanoma. Similar advances in molecular targeted PET imaging can identify molecular pathways that promote disease progression and therefore offer physiological information. Thus, they can be used to assess prognosis, tumor heterogeneity, and identify instances of treatment failure. Numerous agents tested preclinically and clinically demonstrate promising results with high tumor-to-background ratios in both primary and metastatic melanoma tumors. Here, we detail the development and testing of multiple molecular targeted PET-imaging agents, including agents for general oncological imaging and those specifically for PET imaging of melanoma. Of the numerous radiopharmaceuticals evaluated for this purpose, several have made it to clinical trials and showed promising results. Ultimately, these agents may become the standard of care for melanoma imaging if they are able to demonstrate micrometastatic disease and thus provide more accurate information for staging. Furthermore, these agents provide a more accurate way to monitor response to therapy. Patients will be able to receive treatment based on tumor uptake characteristics and may be able to be treated earlier for lesions that with traditional imaging would be subclinical, overall leading to improved outcomes for patients.
format Online
Article
Text
id pubmed-9139963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91399632022-05-28 Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma Vercellino, Laetitia de Jong, Dorine Dercle, Laurent Hosten, Benoit Braumuller, Brian Das, Jeeban Paul Deng, Aileen Moya-Plana, Antoine A’Keen, Camry Yeh, Randy Merlet, Pascal Baroudjian, Barouyr Salvatore, Mary M. Capaccione, Kathleen M. Diagnostics (Basel) Review Melanoma is a deadly disease that often exhibits relentless progression and can have both early and late metastases. Recent advances in immunotherapy and targeted therapy have dramatically increased patient survival for patients with melanoma. Similar advances in molecular targeted PET imaging can identify molecular pathways that promote disease progression and therefore offer physiological information. Thus, they can be used to assess prognosis, tumor heterogeneity, and identify instances of treatment failure. Numerous agents tested preclinically and clinically demonstrate promising results with high tumor-to-background ratios in both primary and metastatic melanoma tumors. Here, we detail the development and testing of multiple molecular targeted PET-imaging agents, including agents for general oncological imaging and those specifically for PET imaging of melanoma. Of the numerous radiopharmaceuticals evaluated for this purpose, several have made it to clinical trials and showed promising results. Ultimately, these agents may become the standard of care for melanoma imaging if they are able to demonstrate micrometastatic disease and thus provide more accurate information for staging. Furthermore, these agents provide a more accurate way to monitor response to therapy. Patients will be able to receive treatment based on tumor uptake characteristics and may be able to be treated earlier for lesions that with traditional imaging would be subclinical, overall leading to improved outcomes for patients. MDPI 2022-04-29 /pmc/articles/PMC9139963/ /pubmed/35626272 http://dx.doi.org/10.3390/diagnostics12051116 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vercellino, Laetitia
de Jong, Dorine
Dercle, Laurent
Hosten, Benoit
Braumuller, Brian
Das, Jeeban Paul
Deng, Aileen
Moya-Plana, Antoine
A’Keen, Camry
Yeh, Randy
Merlet, Pascal
Baroudjian, Barouyr
Salvatore, Mary M.
Capaccione, Kathleen M.
Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
title Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
title_full Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
title_fullStr Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
title_full_unstemmed Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
title_short Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
title_sort translating molecules into imaging—the development of new pet tracers for patients with melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139963/
https://www.ncbi.nlm.nih.gov/pubmed/35626272
http://dx.doi.org/10.3390/diagnostics12051116
work_keys_str_mv AT vercellinolaetitia translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT dejongdorine translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT derclelaurent translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT hostenbenoit translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT braumullerbrian translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT dasjeebanpaul translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT dengaileen translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT moyaplanaantoine translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT akeencamry translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT yehrandy translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT merletpascal translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT baroudjianbarouyr translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT salvatoremarym translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma
AT capaccionekathleenm translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma